GSK plc reports developments across its global biopharma business, including vaccines, respiratory medicines, infectious disease, immunology and oncology programs. Recurring updates include regulatory decisions and clinical evidence for products such as AREXVY, GSK's RSV vaccine, and Exdensur for severe asthma, along with data presentations, product indications and therapeutic-area access initiatives.
GSK news also covers manufacturing and supply agreements, commercial collaborations, public-health grant programs and product partnerships tied to its medicine and vaccine portfolio. As an American Depositary Share issuer, company updates may reflect both parent-company announcements and ADR-related market disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
GSK plc (LSE/NYSE: GSK) has announced its agreement to acquire BELLUS Health Inc. (TSX/NASDAQ: BLU) for US$14.75 per share, totaling an approximate equity value of US$2.0 billion. This acquisition aims to strengthen GSK's specialty medicines and respiratory pipeline, particularly through camlipixant, a selective P2X3 antagonist for refractory chronic cough (RCC), currently in phase III clinical trials with a launch anticipated in 2026. The deal is projected to be accretive to adjusted EPS starting from 2027 and has significant sales potential through 2031.
With an estimated 28 million patients suffering from chronic cough globally, this acquisition addresses a substantial unmet medical need, as no approved medicines currently exist for RCC in the US and EU.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has achieved a $30 million milestone from GSK (LSE/NYSE: GSK) following the initiation of GSK4532990's Phase 2b trial for treating non-alcoholic steatohepatitis (NASH). This investigational RNA interference therapeutic was licensed to GSK in November 2021, with Arrowhead retaining rights for Greater China. The trial, known as HORIZON (NCT05583344), will assess the drug's efficacy and safety in up to 246 participants with pre-cirrhotic NASH. GSK4532990 targets HSD17B13, a gene linked to metabolic protection against NASH.
PathAI has partnered with GSK to conduct the HORIZON Phase 2b clinical trial targeting non-alcoholic steatohepatitis (NASH). This randomized trial will assess the efficacy of GSK4532990 on improving liver histology compared to placebo in patients with advanced fibrosis. PathAI will utilize its AIM-NASH tool for AI-driven histologic evaluation and provide comprehensive pathology services from biopsy analysis to lab services at its Memphis facility. The trial aims to last up to 76 weeks, with treatment lasting up to 52 weeks. This partnership builds on their existing collaboration focusing on drug development in NASH and oncology.